{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:09:29Z","timestamp":1790770169878,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Uveal melanoma (UM) is an orphan disease with a mortality of 80% within one year upon the development of metastatic disease. UM does hardly respond to chemotherapy and kinase inhibitors and is largely resistant to checkpoint inhibition. Hence, further therapy approaches are urgently needed. To improve clinical outcome, we designed a trial employing the 3<jats:sup>rd<\/jats:sup> generation personalized IKK\u03b2-matured RNA-transfected dendritic cell (DC) vaccine which primes T cells and in addition activates NK cells. This ongoing phase I trial [NCT04335890 (<jats:uri>www.clinicaltrials.gov<\/jats:uri>), Eudract: 2018-004390-28 (<jats:uri>www.clinicaltrialsregister.eu<\/jats:uri>)] investigates patients with treatment-naive metastatic UM. Monocytes are isolated by leukapheresis, differentiated to immature DCs, matured with a cytokine cocktail, and activated <jats:italic>via<\/jats:italic> the NF-\u03baB pathway by electroporation with RNA encoding a constitutively active mutant of IKK\u03b2. Three types of antigen-RNA are co-electroporated: i) amplified mRNA of the tumor representing the whole transcriptome, ii) RNA encoding driver mutations identified by exome sequencing, and iii) overexpressed non-mutated tumor antigens detected by transcriptome sequencing. This highly personalized DC vaccine is applied by 9 intravenous infusions in a staggered schedule over one year. Parallel to the vaccination, standard therapy, usually an immune checkpoint blockade (ICB) as mono (anti-PD-1) or combined (anti-CTLA4 and anti-PD-1) regimen is initiated. The coordinated vaccine-induced immune response encompassing tumor-specific T cells and innate NK cells should synergize with ICB, perhaps resulting in measurable clinical responses in this resistant tumor entity. Primary outcome measures of this trial are safety, tolerability and toxicity; secondary outcome measures comprise overall survival and induction of antigen-specific T cells.<\/jats:p>","DOI":"10.3389\/fimmu.2022.785231","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T06:03:00Z","timestamp":1643954580000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKK\u03b2-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Elias A. T.","family":"Koch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Schaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Kummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerold","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Hasumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u00f6rrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Schuler-Thurner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000492391","article-title":"Uveal Melanoma in Ireland","volume":"5","author":"Baily","year":"2019","journal-title":"Ocul Oncol Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.01.032","article-title":"Incidence of Uveal Melanoma in Europe","volume":"114","author":"Virgili","year":"2007","journal-title":"Ophthalmology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal Melanoma: Trends in Incidence, Treatment, and Survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3857\/roj.2020.00318","article-title":"Clinical Management of Uveal Melanoma: A Comprehensive Review With a Treatment Algorithm","volume":"38","author":"Sayan","year":"2020","journal-title":"Radiat Oncol J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/bjophthalmol-2018-313419","article-title":"Ruthenium-106 Versus Iodine-125 Plaque Brachytherapy of 571 Choroidal Melanomas With a Thickness of >\/=5.5 Mm","volume":"104","author":"Fili","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.5.670","article-title":"Assessment of Metastatic Disease Status at Death in 435 Patients With Large Choroidal Melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS Report No. 15","volume":"119","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0538","article-title":"Very Long-Term Prognosis of Patients With Malignant Uveal Melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.07.145","article-title":"Immunotherapy in Melanoma: Recent Advances and Future Directions","volume":"43","author":"Franklin","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression Free and Overall Survival Benchmarks: An International Rare Cancers Initiative (IRCI) Ocular Melanoma Study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study","volume":"39","author":"Pelster","year":"2020","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","volume":"119","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","article-title":"Combined Immune Checkpoint Blockade for Metastatic Uveal Melanoma: A Retrospective, Multi-Center Study","volume":"7","author":"Heppt","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","article-title":"Prognostic Factors and Outcomes in Metastatic Uveal Melanoma Treated With Programmed Cell Death-1 or Combined PD-1\/Cytotoxic T-Lymphocyte Antigen-4 Inhibition","volume":"82","author":"Heppt","year":"2017","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000331","article-title":"Ipilimumab Plus Nivolumab for Patients With Metastatic Uveal Melanoma: A Multicenter, Retrospective Study","volume":"8","author":"Najjar","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.3390\/cancers13133359","article-title":"Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis","volume":"13","author":"Koch","year":"2021","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined Immune Checkpoint Blockade (Anti-PD-1\/Anti-CTLA-4): Evaluation and Management of Adverse Drug Reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejca.2019.01.015","article-title":"Adverse Events 2.0-Let Us Get SERIOs: New Reporting for Adverse Event Outcomes Needed in the Era of Immunooncology","volume":"112","author":"Heinzerling","year":"2019","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000353","article-title":"Immune Checkpoint Inhibitor-Induced Bilateral Vestibulopathy","volume":"44","author":"Koch","year":"2021","journal-title":"J\u00a0Immunother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.9521","article-title":"Redirected T Cell Lysis in Patients With Metastatic Uveal Melanoma With Gp100-Directed TCR IMCgp100: Overall Survival Findings","volume":"36","author":"Sato","year":"2018","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-CT002","article-title":"Abstract CT002: Phase 3 Randomized Trial Comparing Tebentafusp With Investigator's Choice in First Line Metastatic Uveal Melanoma","volume":"81","author":"Piperno-Neumann","year":"2021","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15.15_suppl.e21024","article-title":"Abstract E21024: Dendritic Cell Vaccination in Metastatic Uveal Melanoma as Compassionate Treatment: Immunological and Clinical Responses","volume":"37","author":"Moreira","year":"2019","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-015-0162-z","article-title":"Immunotherapy of Uveal Melanoma: Vaccination Against Cancer. Multicenter Adjuvant Phase 3 Vaccination Study Using Dendritic Cells Laden With Tumor RNA for Large Newly Diagnosed Uveal Melanoma","volume":"112","author":"Schuler-Thurner","year":"2015","journal-title":"Ophthalmologe"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344417","article-title":"Triggering of NF-kappaB in Cytokine-Matured Human DCs Generates Superior DCs for T-Cell Priming in Cancer Immunotherapy","volume":"44","author":"Pfeiffer","year":"2014","journal-title":"Eur J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919891622","article-title":"NF-kappaB Activation Triggers NK-Cell Stimulation by Monocyte-Derived Dendritic Cells","volume":"11","author":"Bosch","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.11.6649","article-title":"Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules","volume":"172","author":"Bonehill","year":"2004","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3180ca7cd6","article-title":"Effective Clinical-Scale Production of Dendritic Cell Vaccines by Monocyte Elutriation Directly in Medium, Subsequent Culture in Bags and Final Antigen Loading Using Peptides or RNA Transfection","volume":"30","author":"Erdmann","year":"2007","journal-title":"J Immunother"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-6481-9_10","article-title":"Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells With Antigens and Functional Proteins","volume":"1499","author":"Gerer","year":"2017","journal-title":"Methods Mol Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0385-1","article-title":"Introduction of Functional Chimeric E\/L-Selectin by RNA Electroporation to Target Dendritic Cells From Blood to Lymph Nodes","volume":"57","author":"Dorrie","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.91438","article-title":"Twelve-Year Survival and Immune Correlates in Dendritic Cell-Vaccinated Melanoma Patients","volume":"2","author":"Gross","year":"2017","journal-title":"JCI Insight"},{"key":"B30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/ddg.14192","article-title":"Step by Step Optimization of mRNA-Electroporated Dendritic Cells During a Phase I\/II Vaccine Trial in Stage IV Cutaneous Melanoma Patients: An Increase in Survival Correlates With Higher Immunoscore in Metastases, and Upregulation of PEBP1 in Peripheral Blood","volume":"18","author":"D\u00f6rrie","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and Tumor Antigen mRNA Electroporated Dendritic Cell Vaccination Plus Ipilimumab: Link Between T-Cell Activation and Clinical Responses in Advanced Melanoma","volume":"8","author":"De Keersmaecker","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/pharmaceutics12020092","article-title":"Therapeutic Cancer Vaccination With Ex Vivo RNA-Transfected Dendritic Cells-An Update","volume":"12","author":"D\u00f6rrie","year":"2020","journal-title":"Pharmaceutics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2007.07.014","article-title":"Uveal Melanoma Expression of Indoleamine 2,3-Deoxygenase: Establishment of an Immune Privileged Environment by Tryptophan Depletion","volume":"85","author":"Chen","year":"2007","journal-title":"Exp Eye Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-1336","article-title":"Expression of Indoleamine 2,3-Dioxygenase in Human Corneal Cells as a Local Immunosuppressive Factor","volume":"48","author":"Ryu","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2016.05.010","article-title":"Safety, Immune and Clinical Responses in Metastatic Melanoma Patients Vaccinated With a Long Peptide Derived From Indoleamine 2,3-Dioxygenase in Combination With Ipilimumab","volume":"18","author":"Bjoern","year":"2016","journal-title":"Cytotherapy"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit With Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"B37","article-title":"Phase I Evaluation of Intravenous Recombinant Human Interleukin 12 in Patients With Advanced Malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-002-0356-5","article-title":"IL-12: A Promising Adjuvant for Cancer Vaccination","volume":"52","author":"Portielje","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/1758834017712630","article-title":"Preclinical Evaluation of NF-kappaB-Triggered Dendritic Cells Expressing the Viral Oncogenic Driver of Merkel Cell Carcinoma for Therapeutic Vaccination","volume":"9","author":"Gerer","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2015.15","article-title":"A New Method to Monitor Antigen-Specific CD8+ T Cells, Avoiding Additional Target Cells and the Restriction to Human Leukocyte Antigen Haplotype","volume":"22","author":"Prommersberger","year":"2015","journal-title":"Gene Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e796","DOI":"10.1371\/journal.pone.0000796","article-title":"NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence","volume":"2","author":"Nielsen","year":"2007","journal-title":"PLoS One"},{"key":"B42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nprot.2012.037","article-title":"Parallel Detection of Antigen-Specific T Cell Responses by Combinatorial Encoding of MHC Multimers","volume":"7","author":"Andersen","year":"2012","journal-title":"Nat Protoc"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0129","article-title":"The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity","volume":"6","author":"Danilova","year":"2018","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.785231\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T06:03:03Z","timestamp":1643954583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.785231\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2022.785231"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.785231","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"article-number":"785231"}}